



3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone (800) 325-5832 (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

Product Information

Anti-FBI-1/Pokemon (C-Terminal)

antibody produced in rabbit, affinity isolated antibody

Product Number **F9429**

Product Description

Anti-FBI-1/Pokemon (C-terminal) is developed in rabbit using as immunogen a synthetic peptide corresponding to amino acids 570-584 of human FBI-1/Pokemon, conjugated to KLH via an N-terminal added cysteine residue. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-FBI-1/Pokemon (C-terminal) recognizes specifically human FBI-1/Pokemon (75 kDa). An additional band may appear at 70 kDa. Applications include immunoblotting and immunoprecipitation. Staining of the FBI-1/Pokemon bands in immunoblotting is specifically inhibited by the immunizing peptide.

The BTB/POZ domain is an evolutionarily conserved protein interaction domain that is found at the N-terminus of various cellular and viral regulator proteins. Members of this family can act as potent transcriptional repressors through the recruitment of histone deacetylases (HDACs) and subsequent chromatin remodeling.¹⁻³ BTB/POZ domain-containing proteins such as PLZF and BCL6 have been implicated in oncogenesis as well as differentiation processes such as myelopoiesis, lymphopoiesis, adipogenesis, and osteoclastogenesis.³⁻⁵

FBI-1/Pokemon, a BTB/POZ containing protein, was characterized as a factor that binds to the HIV-inducer of short transcripts (IST) and was called FBI-1.⁶ It was later identified as a critical factor in oncogenesis and was called Pokemon (POK erythroid myeloid ontogenic factor).⁷ FBI-1/Pokemon is highly expressed in a subset of T-cell lymphoma and B-cell lymphomas, as well as in breast, lung, colon, prostate, and bladder carcinomas. One of the mechanisms by which Pokemon exerts its oncogenic activity is through repression of the tumor suppressor gene ARF through direct binding to the Pokemon-binding site in the ARF promoter.^{7,8}

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Antibody Concentration: ~1 mg/mL

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.

Precautions and Disclaimer

Due to the sodium azide content, a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is also not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: a working antibody concentration of 0.5-1.0 µg/mL is recommended using cell extracts of K-562 cell line.

Immunoprecipitation: 1-2 µg of the antibody immunoprecipitates FBI-1/Pokemon from A431 cell extracts.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining the optimal working dilutions by titration.

References

1. Albagli, O., *et al.*, *Cell Growth & Differ.*, **6**, 1193-1198 (1995).
2. Collins, T., *et al.*, *Mol. Cell. Biol.*, **21**, 3609-3615 (2001).
3. Melnick, A., *et al.*, *Mol. Cell. Biol.*, **22**, 1804-1818 (2002).
4. Kukita, A., *et al.*, *Blood*, **94**, 1987-1997 (1999).
5. Laudes, M., *et al.*, *J. Biol. Chem.*, **279**, 11711-11718 (2004).
6. Morrison, D.J., *et al.*, *Nucl. Acids Res.*, **27**, 1251-1262 (1999).
7. Maeda, T., *et al.*, *Nature*, **433**, 278-285 (2005).
8. Maeda, T., *et al.*, *Cancer Res.*, **65**, 8575-8578 (2005).

NV.KAA.MAM 07/06-1